|
1
|
Du L, Tai W, Zhou Y and Jiang S: Vaccines
for the prevention against the threat of MERS-CoV. Expert Rev
Vaccines. 15:1123–1134. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hui DSC and Zumla A: Severe acute
respiratory syndrome: Historical, epidemiologic, and clinical
features. Infect Dis Clin North Am. 33:869–889. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ramadan N and Shaib H: Middle East
respiratory syndrome coronavirus (MERS-CoV): A review. Germs.
9:35–42. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Donnelly CA, Malik MR, Elkholy A,
Cauchemez S and Van Kerkhove MD: Worldwide reduction in MERS cases
and deaths since 2016. Emerg Infect Dis. 25:1758–1760.
2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z,
Xiang J, Wang Y, Song B, Gu X, et al: Clinical course and risk
factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: A retrospective cohort study. Lancet. 395:1054–1062.
2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Folegatti PM, Harrison K, Preciado-Llanes
L, Lopez FR, Bittaye M, Kim YC, Flaxman A, Bellamy D, Makinson R,
Sheridan J, et al: A single dose of ChAdOx1 Chik vaccine induces
neutralizing antibodies against four chikungunya virus lineages in
a phase 1 clinical trial. Nat Commun. 12(4636)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zeller H, Van Bortel W and Sudre B:
Chikungunya: Its history in Africa and Asia and its spread to new
regions in 2013-2014. J Infect Dis. 214 (Suppl 5):S436–S440.
2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bernasconi V, Kristiansen PA, Whelan M,
Román RG, Bettis A, Yimer SA, Gurry C, Andersen SR, Yeskey D, Mandi
H, et al: Developing vaccines against epidemic-prone emerging
infectious diseases. Bundesgesundheitsblatt Gesundheitsforschung
Gesundheitsschutz. 63:65–73. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zaki AM, Van Boheemen S, Bestebroer TM,
Osterhaus AD and Fouchier RA: Isolation of a novel coronavirus from
a man with pneumonia in Saudi Arabia. N Engl J Med. 367:1814–1820.
2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
World Health Organization (WHO): ‘MERS
situation update, September 2019’. WHO, Geneva, 2019. https://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-september-2019.html.
|
|
11
|
Wang C, Zheng X, Gai W, Wong G, Wang H,
Jin H, Feng N, Zhao Y, Zhang W, Li N, et al: Novel chimeric
virus-like particles vaccine displaying MERS-CoV receptor-binding
domain induce specific humoral and cellular immune response in
mice. Antiviral Res. 140:55–61. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Yu X, Zhang S, Jiang L, Cui Y, Li D, Wang
D, Wang N, Fu L, Shi X, Li Z, et al: Structural basis for the
neutralization of MERS-CoV by a human monoclonal antibody MERS-27.
Sci Rep. 5(13133)2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Letko M, Marzi A and Munster V: Functional
assessment of cell entry and receptor usage for SARS-CoV-2 and
other lineage B betacoronaviruses. Nat Microbiol. 5:562–569.
2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Li F and Du L: MERS coronavirus: An
emerging zoonotic virus. Viruses. 11(663)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara
H, Geng Q, Auerbach A and Li F: Structural basis of receptor
recognition by SARS-CoV-2. Nature. 581:221–224. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Woo PCY, Lau SKP, Chen Y, Wong EYM, Chan
KH, Chen H, Zhang L, Xia N and Yuen KY: Rapid detection of MERS
coronavirus-like viruses in bats: Pote1ntial for tracking MERS
coronavirus transmission and animal origin. Emerg Microbes Infect.
7(18)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cotten M, Watson SJ, Zumla AI, Makhdoom
HQ, Palser AL, Ong SH, Al Rabeeah AA, Alhakeem RF, Assiri A,
Al-Tawfiq JA, et al: Spread, circulation, and evolution of the
Middle East respiratory syndrome coronavirus. mBio. 5:e01062–13.
2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Azhar EI, El-Kafrawy SA, Farraj SA, Hassan
AM, Al-Saeed MS, Hashem AM and Madani TA: Evidence for
camel-to-human transmission of MERS coronavirus. N Engl J Med.
370:2499–2505. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Alshukairi AN, Zheng J, Zhao J, Nehdi A,
Baharoon SA, Layqah L, Bokhari A, Al Johani SM, Samman N, Boudjelal
M, et al: High prevalence of MERS-CoV infection in camel workers in
Saudi Arabia. mBio. 9:e01985–18. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li E, Chi H, Huang P, Yan F, Zhang Y, Liu
C, Wang Z, Li G, Zhang S, Mo R, et al: A novel bacterium-like
particle vaccine displaying the MERS-CoV receptor-binding domain
induces specific mucosal and systemic immune responses in mice.
Viruses. 11(799)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chi H, Zheng X, Wang X, Wang C, Wang H,
Gai W, Perlman S, Yang S, Zhao J and Xia X: DNA vaccine encoding
Middle East respiratory syndrome coronavirus S1 protein induces
protective immune responses in mice. Vaccine. 35:2069–2075.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Al-Amri SS, Abbas AT, Siddiq LA, Alghamdi
A, Sanki MA, Al-Muhanna MK, Alhabbab RY, Azhar EI, Li X and Hashem
AM: Immunogenicity of candidate MERS-CoV DNA vaccines based on the
spike protein. Sci Rep. 7(44875)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ababneh M, Alrwashdeh M and Khalifeh M:
Recombinant adenoviral vaccine encoding the spike 1 subunit of the
Middle East respiratory syndrome coronavirus elicits strong humoral
and cellular immune responses in mice. Vet World. 12:1554–1562.
2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Bodmer BS, Fiedler AH, Hanauer JRH, Prüfer
S and Mühlebach MD: Live-attenuated bivalent measles virus-derived
vaccines targeting Middle East respiratory syndrome coronavirus
induce robust and multifunctional T cell responses against both
viruses in an appropriate mouse model. Virology. 521:99–107.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Langenmayer MC, Lülf-Averhoff AT,
Adam-Neumair S, Fux R, Sutter G and Volz A: Distribution and
absence of generalized lesions in mice following single dose
intramuscular inoculation of the vaccine candidate MVA-MERS-S.
Biologicals. 54:58–62. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Adney DR, Wang L, Van Doremalen N, Shi W,
Zhang Y, Kong WP, Miller MR, Bushmaker T, Scott D, de Wit E, et al:
Efficacy of an adjuvanted Middle East respiratory syndrome
coronavirus spike protein vaccine in dromedary camels and alpacas.
Viruses. 11(212)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Alharbi NK, Qasim I, Almasoud A, Aljami
HA, Alenazi MW, Alhafufi A, Aldibasi OS, Hashem AM, Kasem S,
Albrahim R, et al: Humoral immunogenicity and efficacy of a single
dose of ChAdOx1 MERS vaccine candidate in dromedary camels. Sci
Rep. 9(16292)2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hashem AM, Algaissi A, Agrawal AS, Al-Amri
SS, Alhabbab RY, Sohrab SS, S Almasoud A, Alharbi NK, Peng BH,
Russell M, et al: A highly immunogenic, protective, and safe
adenovirus-based vaccine expressing Middle East respiratory
syndrome coronavirus S1-CD40L fusion protein in a transgenic human
dipeptidyl peptidase 4 mouse model. J Infect Dis. 220:1558–1567.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lemiale F, Haddada H, Nabel GJ, Brough DE,
King CR and Gall JG: Novel adenovirus vaccine vectors based on the
enteric-tropic serotype 41. Vaccine. 25:2074–2084. 2007.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Alharbi NK, Padron-Regalado E, Thompson
CP, Kupke A, Wells D, Sloan MA, Grehan K, Temperton N, Lambe T,
Warimwe G, et al: ChAdOx1 and MVA based vaccine candidates against
MERS-CoV elicit neutralising antibodies and cellular immune
responses in mice. Vaccine. 35:3780–3788. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Liu R, Wang J, Shao Y, Wang X, Zhang H,
Shuai L, Ge J, Wen Z and Bu Z: A recombinant VSV-vectored MERS-CoV
vaccine induces neutralizing antibody and T cell responses in
rhesus monkeys after single dose immunization. Antiviral Res.
150:30–38. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhou Y, Yang Y, Huang J, Jiang S and Du L:
Advances in MERS-CoV vaccines and therapeutics based on the
receptor-binding domain. Viruses. 11(60)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Agnihothram S, Menachery VD, Yount BL Jr,
Lindesmith LC, Scobey T, Whitmore A, Schäfer A, Heise MT and Baric
RS: Development of a broadly accessible Venezuelan equine
encephalitis virus replicon particle vaccine platform. J Virol.
92:e00027–18. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lan J, Yao Y, Deng Y, Chen H, Lu G, Wang
W, Bao L, Deng W, Wei Q, Gao GF, et al: Recombinant receptor
binding domain protein induces partial protective immunity in
rhesus macaques against Middle East respiratory syndrome
coronavirus challenge. EEBioMedicine. 2:1438–1446. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wang Q, Qi J, Yuan Y, Xuan Y, Han P, Wan
Y, Ji W, Li Y, Wu Y, Wang J, et al: Bat origins of MERS-CoV
supported by bat coronavirus HKU4 usage of human receptor CD26.
Cell Host Microbe. 16:328–337. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Liu RQ, Ge JY, Wang JL, Yu S, Zhang HL,
Wang JL, Wen ZY and Bu ZG: Newcastle disease virus-based MERS-CoV
candidate vaccine elicits high-level and lasting neutralizing
antibodies in Bactrian camels. J Integr Agric. 16:2264–2273.
2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Pallesen J, Wang N, Corbett KS, Wrapp D,
Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W,
et al: Immunogenicity and structures of a rationally designed
prefusion MERS-CoV spike antigen. Proc Natl Acad Sci USA.
114:E7348–E7357. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wirblich C, Coleman CM, Kurup D, Abraham
TS, Bernbaum JG, Jahrling PB, Hensley LE, Johnson RF, Frieman MB
and Schnell MJ: One-health: A safe, efficient, dual-use vaccine for
humans and animals against Middle East respiratory syndrome
coronavirus and rabies virus. J Virol. 91:e02040–16.
2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Tai W, Wang Y, Fett CA, Zhao G, Li F,
Perlman S, Jiang S, Zhou Y and Du L: Recombinant receptor-binding
domains of multiple Middle East respiratory syndrome coronaviruses
(MERS-CoVs) induce cross-neutralizing antibodies against divergent
human and camel MERS-CoVs and antibody escape mutants. J Virol.
91:e01651–16. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Papageorgiou N, Lichière J, Baklouti A,
Ferron F, Sévajol M, Canard B and Coutard B: Structural
characterization of the N-terminal part of the MERS-CoV
nucleocapsid by X-ray diffraction and small-angle X-ray scattering.
Acta Crystallogr D Struct Biol. 72:192–202. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zhang L, Li L, Yan L, Ming Z, Jia Z, Lou Z
and Rao Z: Structural and biochemical characterization of
endoribonuclease Nsp15 encoded by Middle East respiratory syndrome
coronavirus. J Virol. 92:e00893–18. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Tang J, Zhang N, Tao X, Zhao G, Guo Y,
Tseng CTK, Jiang S, Du L and Zhou Y: Optimization of antigen dose
for a receptor-binding domain-based subunit vaccine against MERS
coronavirus. Hum Vaccin Immunother. 11:1244–1250. 2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK,
Lu L, Wang L, Debnath AK, Zheng BJ, et al: Identification of a
receptor-binding domain in the S protein of the novel human
coronavirus Middle East respiratory syndrome coronavirus as an
essential target for vaccine development. J Virol. 87:9939–9942.
2013.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Nyon MP, Du L, Tseng CTK, Seid CA, Pollet
J, Naceanceno KS, Agrawal A, Algaissi A, Peng BH, Tai W, et al:
Engineering a stable CHO cell line for the expression of a
MERS-coronavirus vaccine antigen. Vaccine. 36:1853–1862.
2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Tao X, Garron T, Agrawal AS, Algaissi A,
Peng BH, Wakamiya M, Chan TS, Lu L, Du L, Jiang S, et al:
Characterization and demonstration of the value of a lethal mouse
model of Middle East respiratory syndrome coronavirus infection and
disease. J Virol. 90:57–67. 2015.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Hao W, Wojdyla JA, Zhao R, Han R, Das R,
Zlatev I, Manoharan M, Wang M and Cui S: Crystal structure of
Middle East respiratory syndrome coronavirus helicase. PLoS Pathog.
13(e1006474)2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Wang C, Zheng X, Gai W, Zhao Y, Wang H,
Wang H, Feng N, Chi H, Qiu B, Li N, et al: MERS-CoV virus-like
particles produced in insect cells induce specific humoural and
cellular imminity in rhesus macaques. Oncotarget. 8:12686–12694.
2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Coleman CM, Venkataraman T, Liu YV, Glenn
GM, Smith GE, Flyer DC and Frieman MB: MERS-CoV spike nanoparticles
protect mice from MERS-CoV infection. Vaccine. 35:1586–1589.
2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Coleman CM, Liu YV, Mu H, Taylor JK,
Massare M, Flyer DC, Glenn GM, Smith GE and Frieman MB: Purified
coronavirus spike protein nanoparticles induce coronavirus
neutralizing antibodies in mice. Vaccine. 32:3169–3174.
2014.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Kato T, Takami Y, Kumar Deo V and Park EY:
Preparation of virus-like particle mimetic nanovesicles displaying
the S protein of Middle East respiratory syndrome coronavirus using
insect cells. J Biotechnol. 306:177–184. 2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Jung SY, Kang KW, Lee EY, Seo DW, Kim HL,
Kim H, Kwon T, Park HL, Kim H, Lee SM and Nam JH: Heterologous
prime-boost vaccination with adenoviral vector and protein
nanoparticles induces both Th1 and Th2 responses against Middle
East respiratory syndrome coronavirus. Vaccine. 36:3468–3476.
2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Veit S, Jany S, Fux R, Sutter G and Volz
A: CD8+ T cells responding to the Middle East respiratory syndrome
coronavirus nucleocapsid protein delivered by vaccinia virus MVA in
mice. Viruses. 10(718)2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Agrawal AS, Tao X, Algaissi A, Garron T,
Narayanan K, Peng BH, Couch RB and Tseng CTK: Immunization with
inactivated Middle East respiratory syndrome coronavirus vaccine
leads to lung immunopathology on challenge with live virus. Hum
Vaccin Immunother. 12:2351–2356. 2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Deng Y, Lan J, Bao L, Huang B, Ye F, Chen
Y, Yao Y, Wang W, Qin C and Tan W: Enhanced protection in mice
induced by immunization with inactivated whole viruses compare to
spike protein of middle east respiratory syndrome coronavirus.
Emerg Microbes Infect. 7(60)2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Scobey T, Yount BL, Sims AC, Donaldson EF,
Agnihothram SS, Menachery VD, Graham RL, Swanstrom J, Bove PF, Kim
JD, et al: Reverse genetics with a full-length infectious cDNA of
the Middle East respiratory syndrome coronavirus. Proc Natl Acad
Sci USA. 110:16157–16162. 2013.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Modjarrad K, Roberts CC, Mills KT,
Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine
T, Oh MD, et al: Safety and immunogenicity of an anti-Middle East
respiratory syndrome coronavirus DNA vaccine: A phase 1,
open-label, single-arm, dose-escalation trial. Lancet Infect Dis.
19:1013–1022. 2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Muthumani K, Falzarano D, Reuschel EL,
Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A,
Aljuaid A, et al: A synthetic consensus anti-spike protein DNA
vaccine induces protective immunity against Middle East respiratory
syndrome coronavirus in nonhuman primates. Sci Transl Med.
7(301ra132)2015.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Koch T, Dahlke C, Fathi A, Kupke A,
Krähling V, Okba NMA, Halwe S, Rohde C, Eickmann M, Volz A, et al:
Safety and immunogenicity of a modified vaccinia virus Ankara
vector vaccine candidate for Middle East respiratory syndrome: An
open-label, phase 1 trial. Lancet Infect Dis. 20:827–838.
2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Zhao J, Li K, Wohlford-Lenane C,
Agnihothram SS, Fett C, Zhao J, Gale MJ Jr, Baric RS, Enjuanes L,
Gallagher T, et al: Rapid generation of a mouse model for Middle
East respiratory syndrome. Proc Natl Acad Sci USA. 111:4970–4975.
2014.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Folegatti PM, Bittaye M, Flaxman A, Lopez
FR, Bellamy D, Kupke A, Mair C, Makinson R, Sheridan J, Rohde C, et
al: Safety and immunogenicity of a candidate Middle East
respiratory syndrome coronavirus viral-vectored vaccine: A
dose-escalation, open-label, non-randomised, uncontrolled, phase 1
trial. Lancet Infect Dis. 20:816–826. 2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Bosaeed M, Balkhy HH, Almaziad S, Aljami
HA, Alhatmi H, Alanazi H, Alahmadi M, Jawhary A, Alenazi MW,
Almasoud A, et al: Safety and immunogenicity of ChAdOx1 MERS
vaccine candidate in healthy Middle Eastern adults (MERS002): an
open-label, non-randomised, dose-escalation, phase 1b trial. Lancet
Microbe. 3:e11–e20. 2022.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Dolzhikova IV, Grousova DM, Zubkova OV,
Tukhvatulin AI, Kovyrshina AV, Lubenets NL, Ozharovskaia TA, Popova
O, Esmagambetov IB, Shcheblyakov DV, et al: Preclinical studies of
immunogenity, protectivity, and safety of the combined vector
vaccine for prevention of the Middle East respiratory syndrome.
Acta Naturae. 12:114–123. 2020.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Chan JFW, Lau SKP and Woo PCY: The
emerging novel Middle East respiratory syndrome coronavirus: the
‘knowns’ and ‘unknowns’. J Formos Med Assoc. 112:372–381.
2013.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Du L, He Y, Zhou Y, Liu S, Zheng BJ and
Jiang S: The spike protein of SARS-CoV-a target for vaccine and
therapeutic development. Nat Rev Microbiol. 7:226–236.
2009.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Peiris JS, Guan Y and Yuen KY: Severe
acute respiratory syndrome. Nat Med. 10 (12 Suppl):S88–S97.
2004.PubMed/NCBI View
Article : Google Scholar
|
|
66
|
Ge XY, Li JL, Yang XL, Chmura AA, Zhu G,
Epstein JH, Mazet JK, Hu B, Zhang W, Peng C, et al: Isolation and
characterization of a bat SARS-like coronavirus that uses the ACE2
receptor. Nature. 503:535–538. 2013.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Enjuanes L, Dediego ML, Alvarez E, Deming
D, Sheahan T and Baric R: Vaccines to prevent severe acute
respiratory syndrome coronavirus-induced disease. Virus Res.
133:45–62. 2008.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Ithete NL, Stoffberg S, Corman VM,
Cottontail VM, Richards LR, Schoeman MC, Drosten C, Drexler JF and
Preiser W: Close relative of human Middle East respiratory syndrome
coronavirus in bat, South Africa. Emerg Infect Dis. 19:1697–1699.
2013.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Minor PD: Live attenuated vaccines:
Historical successes and current challenges. Virology. 479:379–392.
2015.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Lamirande EW, DeDiego ML, Roberts A,
Jackson JP, Alvarez E, Sheahan T, Shieh WJ, Zaki SR, Baric R,
Enjuanes L and Subbarao K: A live attenuated severe acute
respiratory syndrome coronavirus is immunogenic and efficacious in
golden Syrian hamsters. J Virol. 82:7721–7724. 2008.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Robson F, Khan KS, Le TK, Paris C,
Demirbag S, Barfuss P, Rocchi P and Ng WL: Coronavirus RNA
proofreading: molecular basis and therapeutic targeting. Mol Cell.
79:710–727. 2020.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Graham RL, Becker MM, Eckerle LD, Bolles
M, Denison MR and Baric RS: A live, impaired-fidelity coronavirus
vaccine protects in an aged, immunocompromised mouse model of
lethal disease. Nat Med. 18:1820–1826. 2012.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Menachery VD, Gralinski LE, Mitchell HD,
Dinnon KH III, Leist SR, Yount BL Jr, Graham RL, McAnarney ET,
Stratton KG, Cockrell AS, et al: Middle East respiratory syndrome
coronavirus nonstructural protein 16 is necessary for interferon
resistance and viral pathogenesis. mSphere. 2:e00346–17.
2017.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Stauffer F, El-Bacha T and Da Poian AT:
Advances in the development of inactivated virus vaccines. Recent
Pat Antiinfect Drug Discov. 1:291–296. 2006.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Escriou N, Callendret B, Lorin V,
Combredet C, Marianneau P, Février M and Tangy F: Protection from
SARS coronavirus conferred by live measles vaccine expressing the
spike glycoprotein. Virology. 452:32–41. 2014.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Zuñiga S, Pascual-Iglesias A, Sanchez CM,
Sola I and Enjuanes L: Virulence factors in porcine coronaviruses
and vaccine design. Virus Res. 226:142–151. 2016.PubMed/NCBI View Article : Google Scholar
|
|
77
|
DeDiego ML, Alvarez E, Almazán F, Rejas
MT, Lamirande E, Roberts A, Shieh WJ, Zaki SR, Subbarao K and
Enjuanes L: A severe acute respiratory syndrome coronavirus that
lacks the E gene is attenuated in vitro and in vivo. J Virol.
81:1701–1713. 2007.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Bukreyev A, Lamirande EW, Buchholz UJ,
Vogel LN, Elkins WR, St Claire M, Murphy BR, Subbarao K and Collins
PL: Mucosal immunisation of African green monkeys (Cercopithecus
aethiops) with an attenuated parainfluenza virus expressing the
SARS coronavirus spike protein for the prevention of SARS. Lancet.
363:2122–2127. 2004.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Qin E, Shi H, Tang L, Wang C, Chang G,
Ding Z, Zhao K, Wang J, Chen Z, Yu M, et al: Immunogenicity and
protective efficacy in monkeys of purified inactivated Vero-cell
SARS vaccine. Vaccine. 24:1028–1034. 2006.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Tseng CT, Sbrana E, Iwata-Yoshikawa N,
Newman PC, Garron T, Atmar RL, Peters CJ and Couch RB: Immunization
with SARS coronavirus vaccines leads to pulmonary immunopathology
on challenge with the SARS virus. PLoS One.
7(e35421)2012.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Iwata-Yoshikawa N, Uda A, Suzuki T,
Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T,
Hasegawa H and Nagata N: Effects of Toll-like receptor stimulation
on eosinophilic infiltration in lungs of BALB/c mice immunized with
UV-inactivated severe acute respiratory syndrome-related
coronavirus vaccine. J Virol. 88:8597–8614. 2014.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Chang CY, Hong WWL, Chong P and Wu SC:
Influence of intron and exon splicing enhancers on mammalian cell
expression of a truncated spike protein of SARS-CoV and its
implication for subunit vaccine development. Vaccine. 24:1132–1141.
2006.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Feng Y, Wan M, Wang XJ, Zhang PY, Yu YL
and Wang LY: Expression of predicted B cell epitope peptide in S2
subunit of SARS coronavirus spike protein in E. coli and
identification of its mimic antigenicity. Xi Bao Yu Fen Zi Mian Yi
Xue Za Zhi. 23:113–116. 2007.PubMed/NCBI(In Chinese).
|
|
84
|
Li J, Ulitzky L, Silberstein E, Taylor DR
and Viscidi R: Immunogenicity and protection efficacy of monomeric
and trimeric recombinant SARS coronavirus spike protein subunit
vaccine candidates. Viral Immunol. 26:126–132. 2013.PubMed/NCBI View Article : Google Scholar
|
|
85
|
He Y, Li J, Heck S, Lustigman S and Jiang
S: Antigenic and immunogenic characterization of recombinant
baculovirus-expressed severe acute respiratory syndrome coronavirus
spike protein: Implication for vaccine design. J Virol.
80:5757–5767. 2006.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Du L, Zhao G, Chan CC, Li L, He Y, Zhou Y,
Zheng BJ and Jiang S: A 219-mer CHO-expressing receptor-binding
domain of SARS-CoV S protein induces potent immune responses and
protective immunity. Viral Immunol. 23:211–219. 2010.PubMed/NCBI View Article : Google Scholar
|
|
87
|
He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M
and Jiang S: Receptor-binding domain of SARS-CoV spike protein
induces highly potent neutralizing antibodies: Implication for
developing subunit vaccine. Biochem Biophys Res Commun.
324:773–781. 2004.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Liu RY, Wu LZ, Huang BJ, Huang JL, Zhang
YL, Ke ML, Wang JM, Tan WP, Zhang RH, Chen HK, et al: Adenoviral
expression of a truncated S1 subunit of SARS-CoV spike protein
results in specific humoral immune responses against SARS-CoV in
rats. Virus Res. 112:24–31. 2005.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Wang N, Shang J, Jiang S and Du L: Subunit
vaccines against emerging pathogenic human coronaviruses. Front
Microbiol. 11(298)2020.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Buchholz UJ, Bukreyev A, Yang L, Lamirande
EW, Murphy BR, Subbarao K and Collins PL: Contributions of the
structural proteins of severe acute respiratory syndrome
coronavirus to protective immunity. Proc Natl Acad Sci USA.
101:9804–9809. 2004.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Li YD, Chi WY, Su JH, Ferrall L, Hung CF
and Wu TC: Coronavirus vaccine development: From SARS and MERS to
COVID-19. J Biomed Sci. 27(104)2020.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Bouard D, Alazard-Dany N and Cosset FL:
Viral vectors: From virology to transgene expression. Br J
Pharmacol. 157:153–165. 2009.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Gao W, Tamin A, Soloff A, D'Aiuto L,
Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S and Gambotto A:
Effects of a SARS-associated coronavirus vaccine in monkeys.
Lancet. 362:1895–1896. 2003.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Kobinger GP, Figueredo JM, Rowe T, Zhi Y,
Gao G, Sanmiguel JC, Bell P, Wivel NA, Zitzow LA, Flieder DB, et
al: Adenovirus-based vaccine prevents pneumonia in ferrets
challenged with the SARS coronavirus and stimulates robust immune
responses in macaques. Vaccine. 25:5220–5231. 2007.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Zhang CH, Lu JH, Wang YF, Zheng HY, Xiong
S, Zhang MY, Liu XJ, Li JX, Wan ZY, Yan XG, et al: Immune responses
in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine
prepared from F69 strain. Vaccine. 23:3196–3201. 2005.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Bisht H, Roberts A, Vogel L, Bukreyev A,
Collins PL, Murphy BR, Subbarao K and Moss B: Severe acute
respiratory syndrome coronavirus spike protein expressed by
attenuated vaccinia virus protectively immunizes mice. Proc Natl
Acad Sci USA. 101:6641–6646. 2004.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang
F, Wei Q, He T, Yu W, Yu J, et al: Recombinant modified vaccinia
virus Ankara expressing the spike glycoprotein of severe acute
respiratory syndrome coronavirus induces protective neutralizing
antibodies primarily targeting the receptor binding region. J
Virol. 79:2678–2688. 2005.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Weingartl H, Czub M, Czub S, Neufeld J,
Marszal P, Gren J, Smith G, Jones S, Proulx R, Deschambault Y, et
al: Immunization with modified vaccinia virus Ankara-based
recombinant vaccine against severe acute respiratory syndrome is
associated with enhanced hepatitis in ferrets. J Virol.
78:12672–12676. 2004.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Czub M, Weingartl H, Czub S, He R and Cao
J: Evaluation of modified vaccinia virus Ankara based recombinant
SARS vaccine in ferrets. Vaccine. 23:2273–2279. 2005.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Deming D, Sheahan T, Heise M, Yount B,
Davis N, Sims A, Suthar M, Harkema J, Whitmore A, Pickles R, et al:
Vaccine efficacy in senescent mice challenged with recombinant
SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med.
3(e525)2006.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Kapadia SU, Rose JK, Lamirande E, Vogel L,
Subbarao K and Roberts A: Long-term protection from SARS
coronavirus infection conferred by a single immunization with an
attenuated VSV-based vaccine. Virology. 340:174–182.
2005.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Lokugamage KG, Yoshikawa-Iwata N, Ito N,
Watts DM, Wyde PR, Wang N, Newman P, Kent Tseng CT, Peters C and
Makino S: Chimeric coronavirus-like particles carrying severe acute
respiratory syndrome coronavirus (SCoV) S protein protect mice
against challenge with SCoV. Vaccine. 26:797–808. 2008.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Yang ZY, Kong WP, Huang Y, Roberts A,
Murphy BR, Subbarao K and Nabel GJ: A DNA vaccine induces SARS
coronavirus neutralization and protective immunity in mice. Nature.
428:561–564. 2004.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Martin JE, Louder MK, Holman LA, Gordon
IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M,
et al: A SARS DNA vaccine induces neutralizing antibody and
cellular immune responses in healthy adults in a phase I clinical
trial. Vaccine. 26:6338–6343. 2008.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Lin J, Zhang JS, Su N, Xu JG, Wang N, Chen
JT, Chen X, Liu YX, Gao H, Jia YP, et al: Safety and immunogenicity
from a phase I trial of inactivated severe acute respiratory
syndrome coronavirus vaccine. Antivir Ther. 12:1107–1113.
2007.PubMed/NCBI
|
|
106
|
Tang L, Zhu Q, Qin E, Yu M, Ding Z, Shi H,
Cheng X, Wang C, Chang G, Zhu Q, et al: Inactivated SARS-CoV
vaccine prepared from whole virus induces a high level of
neutralizing antibodies in BALB/c mice. DNA Cell Biol. 23:391–394.
2004.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Leta S, Beyene TJ, De Clercq EM, Amenu K,
Kraemer MUG and Revie CW: Global risk mapping for major diseases
transmitted by Aedes aegypti and Aedes albopictus.
Int J Infect Dis. 67:25–35. 2018.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Vega-Rúa A, Zouache K, Girod R, Failloux
AB and Lourenço-de-Oliveira R: High level of vector competence of
Aedes aegypti and Aedes albopictus from ten American
countries as a crucial factor in the spread of chikungunya virus. J
Virol. 88:6294–6306. 2014.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Harrison VR, Binn LN and Randall R:
Comparative immunogenicities of chikungunya vaccines prepared in
avian and mammalian tissues. Am J Trop Med Hyg. 16:786–791.
1967.PubMed/NCBI
|
|
110
|
Mallilankaraman K, Shedlock DJ, Bao H,
Kawalekar OU, Fagone P, Ramanathan AA, Ferraro B, Stabenow J,
Vijayachari P, Sundaram SG, et al: A DNA vaccine against
chikungunya virus is protective in mice and induces neutralizing
antibodies in mice and nonhuman primates. PLoS Negl Trop Dis.
5(e928)2011.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Tretyakova I, Hearn J, Wang E, Weaver S
and Pushko P: DNA vaccine initiates replication of live attenuated
chikungunya virus in vitro and elicits protective immune response
in mice. J Infect Dis. 209:1882–1890. 2014.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Wang E, Volkova E, Adams AP, Forrester N,
Xiao SY, Frolov I and Weaver SC: Chimeric alphavirus vaccine
candidates for chikungunya. Vaccine. 26:5030–5039. 2008.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Hallengärd D, Kakoulidou M, Lulla A,
Kümmerer BM, Johansson DX, Mutso M, Lulla V, Fazakerley JK, Roques
P, Le Grand R, et al: Novel attenuated chikungunya vaccine
candidates elicit protective immunity in C57BL/6 mice. J Virol.
88:2858–2866. 2014.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Chattopadhyay A, Wang E, Seymour R, Weaver
SC and Rose JK: A chimeric vesiculo/alphavirus is an effective
alphavirus vaccine. J Virol. 87:395–402. 2013.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Plante K, Wang E, Partidos CD, Weger J,
Gorchakov R, Tsetsarkin K, Borland EM, Powers AM, Seymour R,
Stinchcomb DT, et al: Novel chikungunya vaccine candidate with an
IRES-based attenuation and host range alteration mechanism. PLoS
Pathog. 7(e1002142)2011.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Levitt NH, Ramsburg HH, Hasty SE, Repik
PM, Cole FE Jr and Lupton HW: Development of an attenuated strain
of chikungunya virus for use in vaccine production. Vaccine.
4:157–162. 1986.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Edelman R, Tacket CO, Wasserman SS,
Bodison SA, Perry JG and Mangiafico JA: Phase II safety and
immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.
Am J Trop Med Hyg. 62:681–685. 2000.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Kushnir N, Streatfield SJ and Yusibov V:
Virus-like particles as a highly efficient vaccine platform:
Diversity of targets and production systems and advances in
clinical development. Vaccine. 31:58–83. 2012.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Ramsauer K, Schwameis M, Firbas C, Müllner
M, Putnak RJ, Thomas SJ, Desprès P, Tauber E, Jilma B and Tangy F:
Immunogenicity, safety, and tolerability of a recombinant
measles-virus-based chikungunya vaccine: A randomised,
double-blind, placebo-controlled, active-comparator, first-in-man
trial. Lancet Infect Dis. 15:519–527. 2015.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Reisinger EC, Tschismarov R, Beubler E,
Wiedermann U, Firbas C, Loebermann M, Pfeiffer A, Muellner M,
Tauber E and Ramsauer K: Immunogenicity, safety, and tolerability
of the measles-vectored chikungunya virus vaccine MV-CHIK: A
double-blind, randomised, placebo-controlled and active-controlled
phase 2 trial. Lancet. 392:2718–2727. 2019.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Chang LJ, Dowd KA, Mendoza FH, Saunders
JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu Z, Enama ME,
et al: Safety and tolerability of chikungunya virus-like particle
vaccine in healthy adults: A phase 1 dose-escalation trial. Lancet.
384:2046–2052. 2014.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Brandler S, Ruffié C, Combredet C, Brault
JB, Najburg V, Prevost MC, Habel A, Tauber E, Desprès P and Tangy
F: A recombinant measles vaccine expressing chikungunya virus-like
particles is strongly immunogenic and protects mice from lethal
challenge with chikungunya virus. Vaccine. 31:3718–3725.
2013.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Weinbren M, Haddow AJ and Williams M: The
occurrence of chikungunya virus in Uganda. I. Isolation from
mosquitoes. Trans R Soc Trop Med Hyg. 52:253–262. 1958.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Halstead SB and Buescher EL: Hemorrhagic
disease in rodents infected with virus associated with Thai
hemorrhagic fever. Science. 134:475–476. 1961.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Shah KV, Gibbs CJ and Banerjee G:
Virological investigation of the epidemic of haemorrhagic fever in
Calcutta: Isolation of three strains of chikungunya virus. Indian J
Med Res. 52:676–683. 1964.PubMed/NCBI
|
|
126
|
Liu H, Fang G, Wu H, Li Z and Ye Q:
L-cysteine production in Escherichia coli based on rational
metabolic engineering and modular strategy. Biotechnol J.
13(1700695)2018.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Akahata W, Yang ZY, Andersen H, Sun S,
Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG and Rao S: A
virus-like particle vaccine for epidemic chikungunya virus protects
nonhuman primates against infection. Nat Med. 16:334–338.
2010.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Saraswat S, Athmaram TN, Parida M, Agarwal
A, Saha A and Dash PK: Expression and characterization of yeast
derived chikungunya virus like particles (CHIK-VLPs) and its
evaluation as a potential vaccine candidate. PLoS Negl Trop Dis.
10(e0004782)2016.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Wang E, Petrakova O, Adams AP, Aguilar PV,
Kang W, Paessler S, Volk SM, Frolov I and Weaver SC: Chimeric
Sindbis/eastern equine encephalitis vaccine candidates are highly
attenuated and immunogenic in mice. Vaccine. 25:7573–7581.
2007.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Van Den Doel P, Volz A, Roose JM,
Sewbalaksing VD, Pijlman GP, van Middelkoop I, Duiverman V, van de
Wetering E, Sutter G, Osterhaus AD and Martina BE: Recombinant
modified vaccinia virus Ankara expressing glycoprotein E2 of
chikungunya virus protects AG129 mice against lethal challenge.
PLoS Negl Trop Dis. 8(e3101)2014.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Weger-Lucarelli J, Chu H, Aliota MT,
Partidos CD and Osorio JE: A novel MVA vectored chikungunya virus
vaccine elicits protective immunity in mice. PLoS Negl Trop Dis.
8(e2970)2014.PubMed/NCBI View Article : Google Scholar
|
|
132
|
García-Arriaza J, Cepeda V, Hallengärd D,
Sorzano CÓS, Kümmerer BM, Liljeström P and Esteban M: A novel
poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and
protects mice against chikungunya infection. J Virol. 88:3527–3547.
2014.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Wang D, Suhrbier A, Penn-Nicholson A,
Woraratanadharm J, Gardner J, Luo M, Le TT, Anraku I, Sakalian M,
Einfeld D and Dong JY: A complex adenovirus vaccine against
chikungunya virus provides complete protection against viraemia and
arthritis. Vaccine. 29:2803–2809. 2011.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Kumar M, Sudeep AB and Arankalle VA:
Evaluation of recombinant E2 protein-based and whole-virus
inactivated candidate vaccines against chikungunya virus. Vaccine.
30:6142–6149. 2012.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Khan M, Dhanwani R, Rao PVL and Parida M:
Subunit vaccine formulations based on recombinant envelope proteins
of chikungunya virus elicit balanced Th1/Th2 response and
virus-neutralizing antibodies in mice. Virus Res. 167:236–246.
2012.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Chu H, Das SC, Fuchs JF, Suresh M, Weaver
SC, Stinchcomb DT, Partidos CD and Osorio JE: Deciphering the
protective role of adaptive immunity to CHIKV/IRES a novel
candidate vaccine against Chikungunya in the A129 mouse model.
Vaccine. 31:3353–3360. 2013.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Malinoski FJ, Ksiazek T, Ramsburg H,
Lupton HW and Meadors GF (eds): Safety and immunogenicity of a new
chikungunya virus vaccine: double-blind, placebo controlled human
trial. 38th Annual Meeting of the Amer Soc Trop Med Hyg, Section
8.2, 1989.
|
|
138
|
Chen P, Demirji J, Ivleva VB, Horwitz J,
Schwartz R and Arnold F: The transient expression of CHIKV VLP in
large stirred tank bioreactors. Cytotechnology. 71:1079–1093.
2019.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Chen GL, Coates EE, Plummer SH, Carter CA,
Berkowitz N, Conan-Cibotti M, Cox JH, Beck A, O'Callahan M, Andrews
C, et al: Effect of a chikungunya virus-like particle vaccine on
safety and tolerability outcomes: A randomized clinical trial.
JAMA. 323:1369–1377. 2020.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Partidos CD, Paykel J, Weger J, Borland
EM, Powers AM, Seymour R, Weaver SC, Stinchcomb DT and Osorio JE:
Cross-protective immunity against o'nyong-nyong virus afforded by a
novel recombinant chikungunya vaccine. Vaccine. 30:4638–4643.
2012.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Fine DL, Roberts BA, Teehee ML, Terpening
SJ, Kelly CL, Raetz JL, Baker DC, Powers AM and Bowen RA:
Venezuelan equine encephalitis virus vaccine candidate (V3526)
safety, immunogenicity and efficacy in horses. Vaccine.
25:1868–1876. 2007.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Sharma A and Knollmann-Ritschel B: Current
understanding of the molecular basis of Venezuelan equine
encephalitis virus pathogenesis and vaccine development. Viruses.
11(164)2019.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Howley PM, Knipe DM and Whelan S: Fields
virology: Emerging viruses. Lippincott Williams & Wilkins,
2020.
|
|
144
|
Weaver SC, Pfeffer M, Marriott K, Kang W
and Kinney RM: Genetic evidence for the origins of Venezuelan
equine encephalitis virus subtype IAB outbreaks. Am J Trop Med Hyg.
60:441–448. 1999.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Chosewood LC and Wilson DE: Centers for
disease control and prevention: Biosafety in microbiological and
biomedical laboratories, US Department of Health and Human
Services. Public Health Service, Centers for Disease Control and
Prevention, National Institutes of Health, Washington, DC,
2009.
|
|
146
|
Lundberg L, Carey B and Kehn-Hall K:
Venezuelan equine encephalitis virus capsid-the clever caper.
Viruses. 9(279)2017.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Berge TO, Banks IS and Tigertt WD:
Attenua-lion of Venezuelan equine encephalomyelitis virus by ire
vitro cultivation in guinea-pig heart cells. Am J Hyg. 73:209–218.
1961.
|
|
148
|
Paessler S and Weaver SC: Vaccines for
Venezuelan equine encephalitis. Vaccine. 27 (Suppl 4):D80–D85.
2009.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Cole FE Jr, May SW and Robinson DM:
Formalin-inactivated Venezuelan equine encephalomyelitis (Trinidad
strain) vaccine produced in rolling-bottle cultures of chicken
embryo cells. Appl Microbiol. 25:262–265. 1973.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Kinney RM, Tsuchiya KR, Sneider JM and
Trent DW: Molecular evidence for the origin of the widespread
Venezuelan equine encephalitis epizootic of 1969 to 1972. J Gen
Virol. 73:3301–3305. 1992.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Kinney RM, Johnson BJ, Welch JB, Tsuchiya
KR and Trent DW: The full-length nucleotide sequences of the
virulent Trinidad donkey strain of Venezuelan equine encephalitis
virus and its attenuated vaccine derivative, strain TC-83.
Virology. 170:19–30. 1989.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Pittman PR, Makuch RS, Mangiafico JA,
Cannon TL, Gibbs PH and Peters CJ: Long-term duration of detectable
neutralizing antibodies after administration of live-attenuated VEE
vaccine and following booster vaccination with inactivated VEE
vaccine. Vaccine. 14:337–343. 1996.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Rayfield E, Gorelkin L, Cumow R and
Jahrling P: Virus-induced pancreatid disease induced by Venezuelan
equine encephalitis virus. Alterations in glucose tolerance and
insulin release. J Am Diab Assoc. 25:621–623. 1976.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Sharma A, Raviv Y, Puri A, Viard M,
Blumenthal R and Maheshwari RK: Complete inactivation of Venezuelan
equine encephalitis virus by 1,5-iodonaphthylazide. Biochem Biophys
Res Commun. 358:392–398. 2007.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Sharma A, Gupta P, Glass PJ, Parker MD and
Maheshwari RK: Safety and protective efficacy of INA-inactivated
Venezuelan equine encephalitis virus: Implication in vaccine
development. Vaccine. 29:953–959. 2011.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Gupta P, Sharma A, Spurgers KB, Bakken RR,
Eccleston LT, Cohen JW, Honnold SP, Glass PJ and Maheshwari RK:
1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol
challenge with virulent venezuelan equine encephalitis virus.
Vaccine. 34:2762–2765. 2016.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Martin SS, Bakken RR, Lind CM, Garcia P,
Jenkins E, Glass PJ, Parker MD, Hart MK and Fine DL: Comparison of
the immunological responses and efficacy of gamma-irradiated V3526
vaccine formulations against subcutaneous and aerosol challenge
with Venezuelan equine encephalitis virus subtype IAB. Vaccine.
28:1031–1040. 2010.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Fine DL, Jenkins E, Martin SS, Glass P,
Parker MD and Grimm B: A multisystem approach for development and
evaluation of inactivated vaccines for Venezuelan equine
encephalitis virus (VEEV). J Virol Methods. 163:424–432.
2010.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Gaidamakova EK, Myles IA, McDaniel DP,
Fowler CJ, Valdez PA, Naik S, Gayen M, Gupta P, Sharma A, Glass PJ,
et al: Preserving immunogenicity of lethally irradiated viral and
bacterial vaccine epitopes using a radio-protective Mn2+-peptide
complex from Deinococcus. Cell Host Microbe. 12:117–124.
2012.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Gayen M, Gupta P, Morazzani EM,
Gaidamakova EK, Knollmann-Ritschel B, Daly MJ, Glass PJ and
Maheshwari RK: Deinococcus Mn2+-peptide complex: A novel
approach to alphavirus vaccine development. Vaccine. 35:3672–3681.
2017.PubMed/NCBI View Article : Google Scholar
|
|
161
|
Paessler S, Fayzulin RZ, Anishchenko M,
Greene IP, Weaver SC and Frolov I: Recombinant sindbis/Venezuelan
equine encephalitis virus is highly attenuated and immunogenic. J
Virol. 77:9278–9286. 2003.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Paessler S, Ni H, Petrakova O, Fayzulin
RZ, Yun N, Anishchenko M, Weaver SC and Frolov I: Replication and
clearance of Venezuelan equine encephalitis virus from the brains
of animals vaccinated with chimeric SIN/VEE viruses. J Virol.
80:2784–2796. 2006.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Erasmus JH, Seymour RL, Kaelber JT, Kim
DY, Leal G, Sherman MB, Frolov I, Chiu W, Weaver SC and Nasar F:
Novel insect-specific eilat virus-based chimeric vaccine candidates
provide durable, mono-and multivalent, single-dose protection
against lethal alphavirus challenge. J Virol. 92:e01274–17.
2018.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Hu WG, Steigerwald R, Kalla M, Volkmann A,
Noll D and Nagata LP: Protective efficacy of monovalent and
trivalent recombinant MVA-based vaccines against three encephalitic
alphaviruses. Vaccine. 36:5194–5203. 2018.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Kafai NM, Williamson LE, Binshtein E,
Sukupolvi-Petty S, Gardner CL, Liu J, Mackin S, Kim AS, Kose N,
Carnahan RH, et al: Neutralizing antibodies protect mice against
Venezuelan equine encephalitis virus aerosol challenge. J Exp Med.
219(e20212532)2022.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Dupuy LC, Richards MJ, Reed DS and
Schmaljohn CS: Immunogenicity and protective efficacy of a DNA
vaccine against Venezuelan equine encephalitis virus aerosol
challenge in nonhuman primates. Vaccine. 28:7345–7350.
2010.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Lee J, Arun Kumar S, Jhan YY and Bishop
CJ: Engineering DNA vaccines against infectious diseases. Acta
Biomater. 80:31–47. 2018.PubMed/NCBI View Article : Google Scholar
|
|
168
|
Dupuy LC, Locher CP, Paidhungat M,
Richards MJ, Lind CM, Bakken R, Parker MD, Whalen RG and Schmaljohn
CS: Directed molecular evolution improves the immunogenicity and
protective efficacy of a Venezuelan equine encephalitis virus DNA
vaccine. Vaccine. 27:4152–4160. 2009.PubMed/NCBI View Article : Google Scholar
|
|
169
|
Tretyakova I, Lukashevich IS, Glass P,
Wang E, Weaver S and Pushko P: Novel vaccine against Venezuelan
equine encephalitis combines advantages of DNA immunization and a
live attenuated vaccine. Vaccine. 31:1019–1025. 2013.PubMed/NCBI View Article : Google Scholar
|
|
170
|
Rico AB, Phillips AT, Schountz T, Jarvis
DL, Tjalkens RB, Powers AM and Olson KE: Venezuelan and western
equine encephalitis virus E1 liposome antigen nucleic acid
complexes protect mice from lethal challenge with multiple
alphaviruses. Virology. 499:30–39. 2016.PubMed/NCBI View Article : Google Scholar
|
|
171
|
Ni H, Yun NE, Zacks MA, Weaver SC, Tesh
RB, Da Rosa APT, Powers AM, Frolov I and Paessler S: Recombinant
alphaviruses are safe and useful serological diagnostic tools. Am J
Trop Med Hyg. 76:774–781. 2007.PubMed/NCBI
|
|
172
|
Liljeström P and Garoff H: A new
generation of animal cell expression vectors based on the Semliki
Forest virus replicon. Biotechnology (N Y). 9:1356–1361.
1991.PubMed/NCBI View Article : Google Scholar
|
|
173
|
Konopka JL, Thompson JM, Whitmore AC, Webb
DL and Johnston RE: Acute infection with Venezuelan equine
encephalitis virus replicon particles catalyzes a systemic
antiviral state and protects from lethal virus challenge. J Virol.
83:12432–12442. 2009.PubMed/NCBI View Article : Google Scholar
|
|
174
|
Grieder FB, Davis BK, Zhou XD, Chen SJ,
Finkelman FD and Gause WC: Kinetics of cytokine expression and
regulation of host protection following infection with molecularly
cloned Venezuelan equine encephalitis virus. Virology. 233:302–312.
1997.PubMed/NCBI View Article : Google Scholar
|
|
175
|
Phillpotts RJ, O'brien L, Appleton RE,
Carr S and Bennett A: Intranasal immunisation with defective
adenovirus serotype 5 expressing the Venezuelan equine encephalitis
virus E2 glycoprotein protects against airborne challenge with
virulent virus. Vaccine. 23:1615–1623. 2005.PubMed/NCBI View Article : Google Scholar
|
|
176
|
Phillpotts RJ, Jones LD and Howard SC:
Monoclonal antibody protects mice against infection and disease
when given either before or up to 24 h after airborne challenge
with virulent Venezuelan equine encephalitis virus. Vaccine.
20:1497–1504. 2002.PubMed/NCBI View Article : Google Scholar
|
|
177
|
Parker MD, Buckley MJ, Melanson VR, Glass
PJ, Norwood D and Hart MK: Antibody to the E3 glycoprotein protects
mice against lethal Venezuelan equine encephalitis virus infection.
J Virol. 84:12683–12690. 2010.PubMed/NCBI View Article : Google Scholar
|
|
178
|
O'Brien LM, Underwood-Fowler CD, Goodchild
SA, Phelps AL and Phillpotts RJ: Development of a novel monoclonal
antibody with reactivity to a wide range of Venezuelan equine
encephalitis virus strains. Virol J. 6(206)2009.PubMed/NCBI View Article : Google Scholar
|
|
179
|
Alevizatos AC, McKinney RW and Feigin RD:
Live, attenuated Venezuelan equine encephalomyelitis virus vaccine.
I. Clinical effects in man. Am J Trop Med Hyg. 16:762–768.
1967.PubMed/NCBI
|
|
180
|
Pedersen CE Jr, Robinson DM and Cole FE
Jr: Isolation of the vaccine strain of Venezuelan equine
encephalomyelitis virus from mosquitoes in Louisiana. Am J
Epidemiol. 95:490–496. 1972.PubMed/NCBI View Article : Google Scholar
|
|
181
|
Erwin-Cohen R, Porter A, Pittman P, Rossi
C and Dasilva L: Host responses to live-attenuated Venezuelan
equine encephalitis virus (TC-83): Comparison of naïve, vaccine
responder and nonresponder to TC-83 challenge in human peripheral
blood mononuclear cells. Hum Vaccin Immunother. 8:1053–1065.
2012.PubMed/NCBI View Article : Google Scholar
|
|
182
|
Grieder FB, Davis NL, Aronson JF, Charles
PC, Sellon DC, Suzuki K and Johnston RE: Specific restrictions in
the progression of Venezuelan equine encephalitis virus-induced
disease resulting from single amino acid changes in the
glycoproteins. Virology. 206:994–1006. 1995.PubMed/NCBI View Article : Google Scholar
|
|
183
|
Davis NL, Powell N, Greenwald GF, Willis
LV, Johnson BJ, Smith JF and Johnston RE: Attenuating mutations in
the E2 glycoprotein gene of Venezuelan equine encephalitis virus:
Construction of single and multiple mutants in a full-length cDNA
clone. Virology. 183:20–31. 1991.PubMed/NCBI View Article : Google Scholar
|
|
184
|
Edelman R, Ascher MS, Oster CN, Ramsburg
HH, Cole FE and Eddy GA: Evaluation in humans of a new, inactivated
vaccine for Venezuelan equine encephalitis virus (C-84). J Infect
Dis. 140:708–715. 1979.PubMed/NCBI View Article : Google Scholar
|
|
185
|
Johnson DM: Development of rationally
designed live attenuated vaccines for Lassa fever and Venezuelan
equine encephalitis. Electron Theses Diss. (3393)2020.
|
|
186
|
Hannaman D, Dupuy LC, Ellefsen B and
Schmaljohn CS: A phase 1 clinical trial of a DNA vaccine for
Venezuelan equine encephalitis delivered by intramuscular or
intradermal electroporation. Vaccine. 34:3607–3612. 2016.PubMed/NCBI View Article : Google Scholar
|
|
187
|
Powell LA, Miller A, Fox JM, Kose N, Klose
T, Kim AS, Bombardi R, Tennekoon RN, Dharshan de Silva A, Carnahan
RH, et al: Human mAbs broadly protect against arthritogenic
alphaviruses by recognizing conserved elements of the Mxra8
receptor-binding site. Cell Host Microbe. 28:699–711.e7.
2020.PubMed/NCBI View Article : Google Scholar
|
|
188
|
Tupanceska D, Zaid A, Rulli NE, Thomas S,
Lidbury B, Matthaei K, Ramirez R and Mahalingam S: Ross River
virus: An arthritogenic alphavirus of significant importance in the
asia pacific. In: Lal SK (ed). Emerging viral diseases of Southeast
Asia. Vol. 4. Issues Infect Dis. Basel, Karger, pp94-111, 2007.
|
|
189
|
Claflin SB and Webb CE: Ross River virus:
Many vectors and unusual hosts make for an unpredictable pathogen.
PLoS Pathog. 11(e1005070)2015.PubMed/NCBI View Article : Google Scholar
|
|
190
|
Earnest JT, Basore K, Roy V, Bailey AL,
Wang D, Alter G, Fremont DH and Diamond MS: Neutralizing antibodies
against Mayaro virus require Fc effector functions for protective
activity. J Exp Med. 216:2282–2301. 2019.PubMed/NCBI View Article : Google Scholar
|
|
191
|
Fox JM, Long F, Edeling MA, Lin H, van
Duijl-Richter MKS, Fong RH, Kahle KM, Smit JM, Jin J, Simmons G, et
al: Broadly neutralizing alphavirus antibodies bind an epitope on
E2 and inhibit entry and egress. Cell. 163:1095–1107.
2015.PubMed/NCBI View Article : Google Scholar
|
|
192
|
Holzer GW, Coulibaly S, Aichinger G,
Savidis-Dacho H, Mayrhofer J, Brunner S, Schmid K, Kistner O,
Aaskov JG, Falkner FG, et al: Evaluation of an inactivated Ross
River virus vaccine in active and passive mouse immunization models
and establishment of a correlate of protection. Vaccine.
29:4132–4141. 2011.PubMed/NCBI View Article : Google Scholar
|
|
193
|
Aichinger G, Ehrlich HJ, Aaskov JG,
Fritsch S, Thomasser C, Draxler W, Wolzt M, Müller M, Pinl F, Van
Damme P, et al: Safety and immunogenicity of an inactivated whole
virus Vero cell-derived Ross River virus vaccine: A randomized
trial. Vaccine. 29:9376–9384. 2011.PubMed/NCBI View Article : Google Scholar
|
|
194
|
Strauss JH and Strauss EG: The
alphaviruses: Gene expression, replication, and evolution.
Microbiol Rev. 58:491–562. 1994.PubMed/NCBI View Article : Google Scholar
|
|
195
|
Ljungberg K and Liljeström P:
Self-replicating alphavirus RNA vaccines. Expert Rev Vaccines.
14:177–194. 2015.PubMed/NCBI View Article : Google Scholar
|
|
196
|
Frolov I, Hoffman TA, Prágai BM, Dryga SA,
Huang HV, Schlesinger S and Rice CM: Alphavirus-based expression
vectors: Strategies and applications. Proc Natl Acad Sci USA.
93:11371–11377. 1996.PubMed/NCBI View Article : Google Scholar
|
|
197
|
Choo QL, Kuo G, Ralston R, Weiner A, Chien
D, Van Nest G, Han J, Berger K, Thudium K, Kuo C, et al:
Vaccination of chimpanzees against infection by the hepatitis C
virus. Vaccination of chimpanzees against infection by the
hepatitis C virus USA. 91:1294–1298. 1994.PubMed/NCBI View Article : Google Scholar
|
|
198
|
Lópex-Días de Cerio AL, Casares N, Lasarte
JJ, Sarobe P, Pérez-Mediavilla LA, Ruiz M, Prieto J and
Borrás-Cuesta F: T(h)1 but not T(h)0 cell help is efficient to
induce cytotoxic T lymphocytes by immunization with short synthetic
peptides. Int Immunol. 11:2025–2034. 1999.PubMed/NCBI View Article : Google Scholar
|
|
199
|
Shirai M, Akatsuka T, Pendleton CD,
Houghten R, Wychowski C, Mihalik K, Feinstone S and Berzofsky JA:
Induction of cytotoxic T cells to a cross-reactive epitope in the
hepatitis C virus nonstructural RNA polymerase-like protein. J
Virol. 66:4098–4106. 1992.PubMed/NCBI View Article : Google Scholar
|
|
200
|
Leitner WW, Ying H and Restifo NP: DNA and
RNA-based vaccines: Principles, progress and prospects. Vaccine.
18:765–777. 1999.PubMed/NCBI View Article : Google Scholar
|
|
201
|
Baumert TF, Vergalla J, Satoi J, Thomson
M, Lechmann M, Herion D, Greenberg HB, Ito S and Liang TJ:
Hepatitis C virus-like particles synthesized in insect cells as a
potential vaccine candidate. Gastroenterology. 117:1397–1407.
1999.PubMed/NCBI View Article : Google Scholar
|
|
202
|
Makimura M, Miyake S, Akino N, Takamori K,
Matsuura Y, Miyamura T and Saito I: Induction of antibodies against
structural proteins of hepatitis C virus in mice using recombinant
adenovirus. Vaccine. 14:28–36. 1996.PubMed/NCBI View Article : Google Scholar
|
|
203
|
Brinster C and Inchauspé G: DNA vaccines
for hepatitis C virus. Intervirology. 44:143–153. 2001.PubMed/NCBI View Article : Google Scholar
|
|
204
|
Amara RR, Villinger F, Altman JD, Lydy SL,
O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS,
et al: Control of a mucosal challenge and prevention of AIDS by a
multiprotein DNA/MVA vaccine. Science. 292:69–74. 2001.PubMed/NCBI View Article : Google Scholar
|
|
205
|
Ying H, Zaks TZ, Wang RF, Irvine KR,
Kammula US, Marincola FM, Leitner WW and Restifo NP: Cancer therapy
using a self-replicating RNA vaccine. Nat Med. 5:823–827.
1999.PubMed/NCBI View
Article : Google Scholar
|
|
206
|
Berglund P, Fleeton MN, Smerdou C and
Liljeström P: Immunization with recombinant Semliki Forest virus
induces protection against influenza challenge in mice. Vaccine.
17:497–507. 1999.PubMed/NCBI View Article : Google Scholar
|
|
207
|
Fleeton MN, Liljeström P, Sheahan BJ and
Atkins GJ: Recombinant Semliki Forest virus particles expressing
louping ill virus antigens induce a better protective response than
plasmid-based DNA vaccines or an inactivated whole particle
vaccine. J Gen Virol. 81:749–758. 2000.PubMed/NCBI View Article : Google Scholar
|
|
208
|
Ajbani SP, Velhal SM, Kadam RB, Patel VV
and Bandivdekar AH: Immunogenicity of Semliki Forest virus based
self-amplifying RNA expressing Indian HIV-1C genes in mice. Int J
Biol Macromol. 81:794–802. 2015.PubMed/NCBI View Article : Google Scholar
|
|
209
|
Van De Wall S, Ljungberg K, IP PP, Boerma
A, Nijman HW, Liljeström P and Daemen T: Development of a next
generation Semliki Forest virus-based DNA vaccine against cervical
cancer. Hum Gene Ther. 25(A30)2014.
|
|
210
|
Mussgay M and Weiland E: Preparation of
inactivated vaccines against alphaviruses using Semliki Forest
virus-white mouse as a model. I. Inactivation experiments and
evaluation of double inactivated subunit vaccines. Intervirology.
1:259–268. 1973.PubMed/NCBI View Article : Google Scholar
|
|
211
|
Brinster C, Chen M, Boucreux D,
Paranhos-Baccala G, Liljeström P, Lemmonier F and Inchauspé G:
Hepatitis C virus non-structural protein 3-specific cellular immune
responses following single or combined immunization with DNA or
recombinant Semliki Forest virus particles. J Gen Virol.
83:369–381. 2002.PubMed/NCBI View Article : Google Scholar
|
|
212
|
Oñate AA, Donoso G, Moraga-Cid G, Folch H,
Céspedes S and Andrews E: An RNA vaccine based on recombinant
Semliki Forest virus particles expressing the Cu,Zn superoxide
dismutase protein of Brucella abortus induces protective
immunity in BALB/c mice. Infect Immun. 73:3294–3300.
2005.PubMed/NCBI View Article : Google Scholar
|
|
213
|
Jiang X and Baldwin CL: Effects of
cytokines on intracellular growth of Brucella abortus.
Infect Immun. 61:124–134. 1993.PubMed/NCBI View Article : Google Scholar
|
|
214
|
Jones SM and Winter AJ: Survival of
virulent and attenuated strains of Brucella abortus in
normal and gamma interferon-activated murine peritoneal
macrophages. Infect Immun. 60:3011–3014. 1992.PubMed/NCBI View Article : Google Scholar
|
|
215
|
Stevens MG, Pugh GW Jr and Tabatabai LB:
Effects of gamma interferon and indomethacin in preventing
Brucella abortus infections in mice. Infect Immun.
60:4407–4409. 1992.PubMed/NCBI View Article : Google Scholar
|
|
216
|
Zhan Y and Cheers C: Endogenous gamma
interferon mediates resistance to Brucella abortus
infection. Infect Immun. 61:4899–4901. 1993.PubMed/NCBI View Article : Google Scholar
|
|
217
|
Ko J and Splitter GA: Molecular
host-pathogen interaction in brucellosis: Current understanding and
future approaches to vaccine development for mice and humans. Clin
Microbiol Rev. 16:65–78. 2003.PubMed/NCBI View Article : Google Scholar
|
|
218
|
Muñoz-Montesino C, Andrews E, Rivers R,
González-Smith A, Moraga-Cid G, Folch H, Céspedes S and Oñate AA:
Intraspleen delivery of a DNA vaccine coding for superoxide
dismutase (SOD) of Brucella abortus induces SOD-specific
CD4+ and CD8+ T cells. Infect Immun. 72:2081–2087. 2004.PubMed/NCBI View Article : Google Scholar
|
|
219
|
Colmenero P, Berglund P, Kambayashi T,
Biberfeld P, Liljeström P and Jondal M: Recombinant Semliki Forest
virus vaccine vectors: The route of injection determines the
localization of vector RNA and subsequent T cell response. Gene
Ther. 8:1307–1314. 2001.PubMed/NCBI View Article : Google Scholar
|
|
220
|
Smerdou C and Liljestrom P: Two-helper RNA
system for production of recombinant Semliki forest virus
particles. J Virol. 73:1092–1098. 1999.PubMed/NCBI View Article : Google Scholar
|
|
221
|
Berglund P, Quesada-Rolander M, Putkonen
P, Biberfeld G, Thorstensson R and Liljeström P: Outcome of
immunization of cynomolgus monkeys with recombinant Semliki Forest
virus encoding human immunodeficiency virus type 1 envelope protein
and challenge with a high dose of SHIV-4 virus. AIDS Res Hum
Retroviruses. 13:1487–1495. 1997.PubMed/NCBI View Article : Google Scholar
|
|
222
|
Chen M, Hu KF, Rozell B, Örvell C, Morein
B and Liljeström P: Vaccination with recombinant alphavirus or
immune-stimulating complex antigen against respiratory syncytial
virus. J Immunol. 169:3208–3216. 2002.PubMed/NCBI View Article : Google Scholar
|
|
223
|
Singh A, Koutsoumpli G, van de Wall S and
Daemen T: An alphavirus-based therapeutic cancer vaccine: From
design to clinical trial. Cancer Immunol Immunother. 68:849–859.
2019.PubMed/NCBI View Article : Google Scholar
|
|
224
|
Daemen T, Riezebos-Brilman A, Regts J,
Dontje B, van der Zee A and Wilschut J: Superior therapeutic
efficacy of alphavirus-mediated immunization against human
papilloma virus type 16 antigens in a murine tumour model: Effects
of the route of immunization. Antivir Ther. 9:733–742.
2004.PubMed/NCBI
|
|
225
|
Komdeur FL, Singh A, van de Wall S,
Meulenberg JJM, Boerma A, Hoogeboom BN, Paijens ST, Oyarce C, de
Bruyn M, Schuuring E, et al: First-in-human phase I clinical trial
of an SFV-based RNA replicon cancer vaccine against HPV-induced
cancers. Mol Ther. 29:611–625. 2021.PubMed/NCBI View Article : Google Scholar
|
|
226
|
Vignuzzi M, Gerbaud S, van der Werf S and
Escriou N: Naked RNA immunization with replicons derived from
poliovirus and Semliki Forest virus genomes for the generation of a
cytotoxic T cell response against the influenza A virus
nucleoprotein. J Gen Virol. 82:1737–1747. 2001.PubMed/NCBI View Article : Google Scholar
|
|
227
|
Brand D, Lemiale F, Turbica I, Buzelay L,
Brunet S and Barin F: Comparative analysis of humoral immune
responses to HIV type 1 envelope glycoproteins in mice immunized
with a DNA vaccine, recombinant Semliki Forest virus RNA, or
recombinant Semliki Forest virus particles. AIDS Res Hum
Retroviruses. 14:1369–1377. 1998.PubMed/NCBI View Article : Google Scholar
|
|
228
|
Zhou X, Berglund P, Rhodes G, Parker SE,
Jondal M and Liljeström P: Self-replicating Semliki Forest virus
RNA as recombinant vaccine. Vaccine. 12:1510–1514. 1994.PubMed/NCBI View Article : Google Scholar
|
|
229
|
Johansson DX, Ljungberg K, Kakoulidou M
and Liljeström P: Intradermal electroporation of naked replicon RNA
elicits strong immune responses. PLoS One. 7(e29732)2012.PubMed/NCBI View Article : Google Scholar
|
|
230
|
Phenix KV, Wark K, Luke CJ, Skinner MA,
Smyth JA, Mawhinney KA and Todd D: Recombinant Semliki Forest virus
vector exhibits potential for avian virus vaccine development.
Vaccine. 19:3116–3123. 2001.PubMed/NCBI View Article : Google Scholar
|
|
231
|
Goo J, Jeong Y, Park YS, Yang E, Jung DI,
Rho S, Park U, Sung H, Park PG, Choi JA, et al: Characterization of
novel monoclonal antibodies against MERS-coronavirus spike protein.
Virus Res. 278(197863)2020.PubMed/NCBI View Article : Google Scholar
|
|
232
|
Heinz FX, Holzmann H, Essl A and Kundi M:
Field effectiveness of vaccination against tick-borne encephalitis.
Vaccine. 25:7559–7567. 2007.PubMed/NCBI View Article : Google Scholar
|
